145 related articles for article (PubMed ID: 37565730)
1. Identification of potential inhibitors of HER2 targeting breast cancer-a structure-based drug design approach.
Singh G; Al-Fahad D; Al-Zrkani MK; Chaudhuri TK; Soni H; Tandon S; Narasimhaji CV; Azam F; Patil R
J Biomol Struct Dyn; 2023 Aug; ():1-18. PubMed ID: 37565730
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potential HER2 inhibitors from
Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
[TBL] [Abstract][Full Text] [Related]
3. Identification of HER2 inhibitors from curcumin derivatives using combination of
Saibu OA; Singh G; Olugbodi SA; Oluwafemi AT; Ajayi TM; Hammed SO; Oladipo OO; Odunitan TT; Omoboyowa DA
J Biomol Struct Dyn; 2023; 41(21):12328-12337. PubMed ID: 36752338
[TBL] [Abstract][Full Text] [Related]
4. Targeting protein tyrosine phosphatase to unravel possible inhibitors for Streptococcus pneumoniae using molecular docking, molecular dynamics simulations coupled with free energy calculations.
Zaman Z; Khan S; Nouroz F; Farooq U; Urooj A
Life Sci; 2021 Jan; 264():118621. PubMed ID: 33164832
[TBL] [Abstract][Full Text] [Related]
5. Potential target identification for breast cancer and screening of small molecule inhibitors: A bioinformatics approach.
Agarwal S; Kashaw SK
J Biomol Struct Dyn; 2021 Apr; 39(6):1975-1989. PubMed ID: 32186248
[TBL] [Abstract][Full Text] [Related]
6. Screening, Docking, and Molecular Dynamics Study of Natural Compounds as an Anti-HER2 for the Management of Breast Cancer.
Sohrab SS; Kamal MA
Life (Basel); 2022 Oct; 12(11):. PubMed ID: 36362883
[TBL] [Abstract][Full Text] [Related]
7. Ligand and structure based virtual screening of chemical databases to explore potent small molecule inhibitors against breast invasive carcinoma using recent computational technologies.
Agarwal S; Dixit A; Kashaw SK
J Mol Graph Model; 2020 Jul; 98():107591. PubMed ID: 32234678
[TBL] [Abstract][Full Text] [Related]
8. Molecular docking study and molecular dynamic simulation of human cyclooxygenase-2 (COX-2) with selected eutypoids.
Taidi L; Maurady A; Britel MR
J Biomol Struct Dyn; 2022 Feb; 40(3):1189-1204. PubMed ID: 32990169
[TBL] [Abstract][Full Text] [Related]
9. Atomic level and structural understanding of natural ligands inhibiting
Sunder Raj D; Kesavan DK; Kottaisamy CPD; Kumar VP; Hopper W; Sankaran U
J Biomol Struct Dyn; 2023 May; 41(8):3440-3461. PubMed ID: 35293845
[No Abstract] [Full Text] [Related]
10. Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach.
Lamichhane S; Rai RP; Khatri A; Adhikari R; Shrestha BG; Shrestha SK
J Biomol Struct Dyn; 2023 Feb; 41(3):897-911. PubMed ID: 34957911
[TBL] [Abstract][Full Text] [Related]
11. Screening of phytochemicals from
Yasmeen N; Ahmad Chaudhary A; K Niraj RR; Lakhawat SS; Sharma PK; Kumar V
J Biomol Struct Dyn; 2023 Dec; ():1-43. PubMed ID: 38141177
[TBL] [Abstract][Full Text] [Related]
12. In silico identification of potential Hsp90 inhibitors via ensemble docking, DFT and molecular dynamics simulations.
Rezvani S; Ebadi A; Razzaghi-Asl N
J Biomol Struct Dyn; 2022; 40(21):10665-10676. PubMed ID: 34286666
[TBL] [Abstract][Full Text] [Related]
13. New molecular insights for 4
Mehta CC; Rohit S; Patel S; Bhatt HG
J Biomol Struct Dyn; 2023; 41(22):13496-13508. PubMed ID: 36755438
[TBL] [Abstract][Full Text] [Related]
14. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
[TBL] [Abstract][Full Text] [Related]
15. Assessment of iridoids and their similar structures as antineoplastic drugs by
Neupane P; Adhikari Subin J; Adhikari R
J Biomol Struct Dyn; 2024 Feb; ():1-16. PubMed ID: 38345021
[TBL] [Abstract][Full Text] [Related]
16. Screening of Potential Inhibitors Targeting the Main Protease Structure of SARS-CoV-2 via Molecular Docking, and Approach with Molecular Dynamics, RMSD, RMSF, H-Bond, SASA and MMGBSA.
da Fonseca AM; Caluaco BJ; Madureira JMC; Cabongo SQ; Gaieta EM; Djata F; Colares RP; Neto MM; Fernandes CFC; Marinho GS; Dos Santos HS; Marinho ES
Mol Biotechnol; 2023 Jul; ():. PubMed ID: 37490200
[TBL] [Abstract][Full Text] [Related]
17. Molecular docking and molecular dynamics studies of natural products unravel potential inhibitors against OmpA of
Singothu S; Devsani N; Jahidha Begum P; Maddi D; Bhandari V
J Biomol Struct Dyn; 2023 Aug; ():1-12. PubMed ID: 37646649
[TBL] [Abstract][Full Text] [Related]
18. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
Kalirajan R; Pandiselvi A; Gowramma B; Balachandran P
Curr Drug Res Rev; 2019; 11(2):118-128. PubMed ID: 31513003
[TBL] [Abstract][Full Text] [Related]
19. Integrated virtual screening and molecular dynamics simulation approaches revealed potential natural inhibitors for DNMT1 as therapeutic solution for triple negative breast cancer.
Bashir Y; Noor F; Ahmad S; Tariq MH; Qasim M; Tahir Ul Qamar M; Almatroudi A; Allemailem KS; Alrumaihi F; Alshehri FF
J Biomol Struct Dyn; 2024; 42(3):1099-1109. PubMed ID: 37021492
[TBL] [Abstract][Full Text] [Related]
20. Computational insights into overcoming resistance mechanisms in targeted therapies for advanced breast cancer: focus on EGFR and HER2 co-inhibition.
Abdulaziz O; Khan FR; Alharthi NS; Alhuthali HM; Hazazi A; Alzahrani HA; Gharib AF; Alsalmi OA; Hawsawi NM; Alhazmi AY
J Biomol Struct Dyn; 2024 Jan; ():1-12. PubMed ID: 38234016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
